NCT06915766 2026-03-09Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic MastocytosisCogent Biosciences, Inc.Available
NCT05362773 2026-01-13A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesMacroGenicsPhase 1 Recruiting130 enrolled
NCT03580655 2025-04-30(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisBlueprint Medicines CorporationPhase 2 Completed107 enrolled 1 FDA